Director Steven Kornfeld filed a Form 4 with the SEC on August 27, 2026, reporting the disposition of all directly held common stock, stock options, and restricted stock units in Forte Biosciences, Inc. (NASDAQ:FBRX) following the completion of a merger with argenx BV.
Key Highlights
- Full disposition: Steven Kornfeld disposed of 3,960 shares of common stock on August 27, 2026, leaving a beneficial ownership of 0 shares.
- Merger consideration: Shares were exchanged for $77.00 per share in cash, net to the seller, without interest, subject to required withholding tax.
- Merger parties: The transaction involved Forte Biosciences, Inc., argenx BV as Parent, and Avena Merger Sub Inc. as a wholly owned subsidiary of Parent, under a Merger Agreement dated July 26, 2026.
- Options canceled: Seven stock option grants covering a combined 38,000 shares were disposed of on August 27, 2026, with resulting beneficial ownership of 0 in each case.
- RSUs canceled: 18,353 restricted stock units were canceled and converted into the right to receive a lump-sum cash payment equal to $77.00 multiplied by the number of units, subject to applicable withholding taxes.
- Post-merger status: According to the filing, Forte Biosciences survived the merger as a wholly owned subsidiary of argenx BV.
Kornfeld's Holdings Reduced to Zero Following Forte Biosciences Merger Closing
According to the filing, all transactions reported were carried out under the Agreement and Plan of Merger dated July 26, 2026, among Forte Biosciences, Inc., argenx BV, and Avena Merger Sub Inc. The filing states that shares of common stock tendered prior to the expiration of the offer were exchanged for $77.00 per share in cash, and that after completion of the tender offer, Avena Merger Sub Inc. merged with and into Forte Biosciences, with Forte Biosciences surviving as a wholly owned subsidiary of argenx BV.
The filing reports that Kornfeld's 3,960 shares of common stock were disposed of with transaction code "U" on August 27, 2026, reducing his direct beneficial ownership to 0. Seven separate stock option grants, with exercise prices ranging from $7.54 to $888.50 per share, were also disposed of on the same date. The filing explains that options with a per-share exercise price below the $77.00 merger consideration were canceled and converted into the right to receive a cash payment equal to the excess of the merger consideration over the exercise price, multiplied by the number of shares subject to each option. Options with an exercise price equal to or greater than the merger consideration were canceled with no consideration payable.
In addition, the filing discloses that 18,353 restricted stock units were canceled and converted into the right to receive a lump-sum cash payment equal to $77.00 multiplied by the total number of shares subject to the RSUs immediately prior to the effective time of the merger, subject to applicable withholding taxes. Following all reported transactions, Kornfeld's beneficial ownership in each security category stood at 0. The form was signed by Paul A. Wagner, Ph.D., as Attorney-in-Fact, on August 27, 2026.
What Was Disclosed
This Form 4 reported the complete disposition of Steven Kornfeld's directly held common stock, stock options, and restricted stock units in Forte Biosciences, Inc. (NASDAQ:FBRX) on August 27, 2026, in connection with the closing of the merger with argenx BV at $77.00 per share.



Please wait processing your request...